An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of...
| Publicado en: | CHEST Vol. 143; no. 5; pp. 1478 - 1480 |
|---|---|
| Autores principales: | , , |
| Formato: | case study Journal Article |
| Publicado: |
American College of Chest Physicians
2013 May
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class. |
|---|